The long-term goal of Project PRIORITY is to empower the EGFR Resisters community to have an impact on treatment development and future research.
Lung cancer patients harboring mutations in the EGFR gene represent a significant number of the patients diagnosed with non-small cell lung cancer (NSCLC). Approximately 10% to 15% of patients with NSCLC in the United States and 35% in Asia have an EGFR mutation. In the US, more than 20,000 people with EGFR-positive lung cancer are diagnosed each year. Although there has been an increase in progression-free survival in patients due to EGFR tyrosine kinase inhibitors (TKIs), patients eventually develop resistance to these drugs. With each generation of TKIs developed, more mechanisms of resistance are discovered; therefore, the development of drugs to target resistance mutations and other mechanisms of resistance is desperately needed.
The Patient Reported Initiative On Resistance, Incidence, Treatment studY (Project PRIORITY) is a patient-founded and patient-driven research partnership between the EGFR Resisters and LUNGevity Foundation. The study team is interested in understanding the treatment experience of EGFR-positive lung cancer patients. Specifically, the team would like to:
- Understand the demographics and needs of the EGFR-positive lung cancer community
- Identify areas for improvement in diagnosis and treatment
- Give voice to patient concerns regarding risk factors, symptoms, and side effects of treatments
The baseline survey and the longitudinal survey for Project PRIORITY have now concluded. Thank you for your support of Project PRIORITY. We will post more results here after analysis is completed.
If you have any questions or concerns about the survey, please contact the Principal Investigator, Upal Basu Roy, PhD, MPH, Vice President of Research at LUNGevity Foundation, at ubasuroy@LUNGevity.org. You can also read the study FAQs to learn more about Project PRIORITY.